Labège, France, March 19th 2024. Antabio SAS, a clinical stage biopharmaceutical company developing novel treatments for severe drug-resistant
bacterial infections, is pleased to announce the appointment of Dr. Erick Lelouche as Chairman of the Board of Directors.
Before joining the Board of Antabio, Erick Lelouche was Chair of the Boehringer Ingelheim Group in France, a position he has held since 2019. Erick is a graduate of the National Veterinary School of Nantes and of the University School of Management of Montpellier. He has held various senior executive positions in large pharmaceutical companies, such as Pfizer and Boehringer Ingelheim. At Boehringer Ingelheim he served as Director of the Animal
Health division then as Marketing Director for Human Health where he launched several major products, particularly in cardiology and pulmonology. In January 2017, he became President of Boehringer Ingelheim Animal Health in France and then Chair of the Boehringer Ingelheim Group in France in 2019.
“We are very pleased to welcome Erick Lelouche to the Antabio Board” said Marc Lemonnier, Chief Executive Officer and founder of Antabio. “Erick’s deep industry experience and One Health perspective will be invaluable to Antabio as we continue to develop our life-saving treatments for patients suffering from the consequences of antimicrobial resistance”.
“I am honored to join the Antabio pioneering team led by Marc Lemonnier at the forefront of the fight against antimicrobial resistance” Erick Lelouche said. “I am confident that together, by harnessing our collective expertise, we will make meaningful impact for the benefit of patients suffering from drug-resistant infections worldwide”.
About MEM-ANT3310
Carbapenems such as meropenem are the cornerstone of therapies for many life-threatening infections. Resistance to carbapenems is considered a critical priority by the World Health Organisation (WHO) and Centre for Disease Control and Prevention (CDC) because it is a major cause of treatment failure, increased mortality, and huge economic costs.
Bacteria resistant to carbapenems produce β-lactamase enzymes that render antibiotics, such as meropenem, ineffective. ANT3310 inhibits a broad range of β-lactamases, including the Klebsiella pneumoniae carbapenemases (KPC) and oxacillin-hydrolysing (OXA) type enzymes found in CarbapenemResistant Enterobacterales (CRE) and most importantly Carbapenem-Resistant Acinetobacter baumannii (CRAB). The combination of this potent β-lactamase inhibitor with the antibiotic meropenem (MEMANT3310) therefore provides a critical solution for the treatment of serious infections that may be caused by MDR pathogens, such as hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP).
MEM-ANT3310 has received qualified infectious disease product (QIDP) status from the FDA in 2020 for complicated urinary tract infections (cUTI), complicated intra-abdominal infections (cIAI) and HABP and VABP
About Antabio
Antabio is a clinical stage biopharmaceutical company developing novel and highly differentiated antibacterial treatments of drug-resistant infections as defined by the CDC and WHO’s critical priority pathogens, with a particular focus on life-threatening respiratory infections, including carbapenem-resistant nosocomial pneumonia and chronic pulmonary diseases.
In November 2023, the Company completed a €25m series B financing round with subscriptions from the AMR Action Fund, the EIC Fund and from the company’s historical investors including BNP Paribas Développement, Relyens Innovation Santé / Turenne Capital, IRDI Capital Investment and Christophe Ricard, the former President of OM Pharma. The company’s lead program, MEMANT3310, is being developed for the treatment of hospital-acquired infections such as nosocomial pneumonia caused by carbapenem-resistant Acinetobacter baumannii (CRAB) and carbapenem-resistant Enterobacterales (CRE).
Antabio’s portfolio also includes the PEi program aimed at developing a groundbreaking, novel class, novel mode of action inhalation treatment of Pseudomonas aeruginosa (PA) infections, particularly those affecting patients with chronic pulmonary diseases (such as Bronchiectasis, Cystic Fibrosis and COPD).
Contact Information
Carine Danaire, Info@antabio.com